Symbols / MIST Stock $1.91 +0.79% Milestone Pharmaceuticals Inc.
MIST (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-12-16 | main | Wells Fargo | Overweight → Overweight | $8 |
| 2025-12-15 | up | TD Cowen | Hold → Buy | $8 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-09-11 | init | Wells Fargo | — → Overweight | $4 |
| 2025-04-01 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | init | Rodman & Renshaw | — → Buy | $9 |
| 2024-07-01 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-05 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-12-27 | main | TD Cowen | Outperform → Outperform | $9 |
- Biotech Milestone pairs May 13 results with investor webcast - Stock Titan Wed, 06 May 2026 12
- $MIST stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 08 Apr 2026 07
- MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN Fri, 24 Apr 2026 04
- Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality - Seeking Alpha Sat, 14 Mar 2026 07
- Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance ue, 16 Dec 2025 08
- [144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan hu, 16 Apr 2026 07
- All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance ue, 27 Jan 2026 08
- Milestone Pharmaceuticals (NASDAQ: MIST) to vote on equity plan and pay - Stock Titan hu, 30 Apr 2026 20
- Milestone to enroll 450 in real-world study of heart-rhythm spray - Stock Titan Fri, 10 Apr 2026 07
- Insider Sale: Chief Medical Officer of $MIST Sells 58,007 Shares | MIST Stock News - Quiver Quantitative Wed, 28 Jan 2026 08
- Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan hu, 02 Apr 2026 12
- MILESTONE PHARMACEUTICLS ($MIST) Releases Q4 2025 Earnings - Quiver Quantitative Fri, 20 Mar 2026 07
- Milestone (MIST) CEO sells 36,500 shares under Rule 10b5-1 plan - Stock Titan Mon, 20 Apr 2026 07
- Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan hu, 12 Mar 2026 07
- Milestone will stream its Needham healthcare conference talk on Apr. 13 - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.55
|
0.00
-100.00%
|
1.00
-80.00%
|
5.00
|
| Operating Revenue |
|
1.55
|
0.00
-100.00%
|
1.00
-80.00%
|
5.00
|
| Operating Expense |
|
63.69
+51.27%
|
42.10
-32.20%
|
62.10
-3.94%
|
64.64
|
| Research And Development |
|
18.11
+26.13%
|
14.36
-53.76%
|
31.05
-22.04%
|
39.83
|
| Selling General And Administration |
|
45.58
+64.27%
|
27.75
-10.63%
|
31.05
+25.12%
|
24.81
|
| Selling And Marketing Expense |
|
28.30
+157.24%
|
11.00
-27.20%
|
15.11
+66.18%
|
9.10
|
| General And Administrative Expense |
|
17.27
+3.18%
|
16.74
+5.08%
|
15.93
+1.36%
|
15.72
|
| Other Gand A |
|
17.27
+3.18%
|
16.74
+5.08%
|
15.93
+1.36%
|
15.72
|
| Total Expenses |
|
63.69
+51.27%
|
42.10
-32.20%
|
62.10
-3.94%
|
64.64
|
| Operating Income |
|
-62.14
-47.59%
|
-42.10
+31.09%
|
-61.10
-2.44%
|
-59.64
|
| Total Operating Income As Reported |
|
-62.14
-47.59%
|
-42.10
+31.09%
|
-61.10
-2.44%
|
-59.64
|
| EBITDA |
|
-59.11
-56.23%
|
-37.83
+33.67%
|
-57.04
+2.16%
|
-58.30
|
| Normalized EBITDA |
|
-59.11
-56.23%
|
-37.83
+33.67%
|
-57.04
+2.16%
|
-58.30
|
| Reconciled Depreciation |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| EBIT |
|
-59.22
-56.10%
|
-37.94
+33.59%
|
-57.13
+2.15%
|
-58.39
|
| Net Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Pretax Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Non Operating Interest Income Expense |
|
-0.92
-257.46%
|
0.58
-58.74%
|
1.41
+12.68%
|
1.25
|
| Interest Expense Non Operating |
|
3.84
+7.18%
|
3.58
+40.21%
|
2.55
|
0.00
|
| Net Interest Income |
|
-0.92
-257.46%
|
0.58
-58.74%
|
1.41
+12.68%
|
1.25
|
| Interest Expense |
|
3.84
+7.18%
|
3.58
+40.21%
|
2.55
|
0.00
|
| Interest Income Non Operating |
|
2.92
-29.88%
|
4.16
+4.97%
|
3.97
+216.35%
|
1.25
|
| Interest Income |
|
2.92
-29.88%
|
4.16
+4.97%
|
3.97
+216.35%
|
1.25
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income From Continuing Operation Net Minority Interest |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income From Continuing And Discontinued Operation |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income Continuous Operations |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Normalized Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income Common Stockholders |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Diluted EPS |
|
—
|
-0.67
+51.80%
|
-1.39
-0.72%
|
-1.38
|
| Basic EPS |
|
—
|
-0.67
+51.80%
|
-1.39
-0.72%
|
-1.38
|
| Basic Average Shares |
|
—
|
62.21
+44.82%
|
42.96
+1.19%
|
42.45
|
| Diluted Average Shares |
|
—
|
62.21
+44.82%
|
42.96
+1.19%
|
42.45
|
| Diluted NI Availto Com Stockholders |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
75.23
|
| Current Assets |
|
73.03
|
| Cash Cash Equivalents And Short Term Investments |
|
66.00
|
| Cash And Cash Equivalents |
|
13.76
|
| Other Short Term Investments |
|
52.24
|
| Receivables |
|
3.85
|
| Other Receivables |
|
2.42
|
| Taxes Receivable |
|
0.91
|
| Accrued Interest Receivable |
|
0.53
|
| Inventory |
|
—
|
| Prepaid Assets |
|
3.18
|
| Total Non Current Assets |
|
2.19
|
| Net PPE |
|
2.19
|
| Gross PPE |
|
2.38
|
| Accumulated Depreciation |
|
-0.19
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.38
|
| Other Properties |
|
1.92
|
| Leases |
|
0.09
|
| Total Liabilities Net Minority Interest |
|
58.45
|
| Current Liabilities |
|
7.23
|
| Payables And Accrued Expenses |
|
5.97
|
| Payables |
|
3.98
|
| Accounts Payable |
|
3.98
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
1.99
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.71
|
| Current Debt And Capital Lease Obligation |
|
0.55
|
| Current Capital Lease Obligation |
|
0.55
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
51.23
|
| Long Term Debt And Capital Lease Obligation |
|
51.23
|
| Long Term Debt |
|
49.77
|
| Long Term Capital Lease Obligation |
|
1.46
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
16.77
|
| Common Stock Equity |
|
16.77
|
| Capital Stock |
|
260.50
|
| Common Stock |
|
260.50
|
| Share Issued |
|
33.48
|
| Ordinary Shares Number |
|
33.48
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
33.83
|
| Retained Earnings |
|
-326.03
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
| Total Equity Gross Minority Interest |
|
16.77
|
| Total Capitalization |
|
66.54
|
| Working Capital |
|
65.81
|
| Invested Capital |
|
66.54
|
| Total Debt |
|
51.77
|
| Net Debt |
|
36.01
|
| Capital Lease Obligations |
|
2.00
|
| Net Tangible Assets |
|
16.77
|
| Tangible Book Value |
|
16.77
|
| Foreign Currency Translation Adjustments |
|
—
|
| Other Equity Interest |
|
48.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-49.04
-70.00%
|
-28.85
+37.86%
|
-46.42
+11.52%
|
-52.47
|
| Cash Flow From Continuing Operating Activities |
|
-49.04
-70.00%
|
-28.85
+37.86%
|
-46.42
+11.52%
|
-52.47
|
| Net Income From Continuing Operations |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Depreciation Amortization Depletion |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Depreciation |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Depreciation And Amortization |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Other Non Cash Items |
|
3.84
+7.23%
|
3.58
+40.17%
|
2.55
|
—
|
| Stock Based Compensation |
|
7.46
+29.17%
|
5.78
-39.42%
|
9.53
+5.37%
|
9.05
|
| Operating Gains Losses |
|
—
|
0.01
|
—
|
0.14
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
|
0.00
-100.00%
|
0.14
|
| Change In Working Capital |
|
2.68
-26.59%
|
3.66
+194.13%
|
1.24
+138.11%
|
-3.26
|
| Change In Receivables |
|
-1.12
-176.51%
|
1.46
+155.34%
|
-2.64
-261.37%
|
-0.73
|
| Change In Inventory |
|
-0.65
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.03
-97.83%
|
1.34
-52.67%
|
2.83
+265.71%
|
-1.71
|
| Change In Payables And Accrued Expense |
|
4.43
+406.51%
|
0.88
-15.54%
|
1.04
+214.22%
|
-0.91
|
| Change In Other Working Capital |
|
-0.01
+29.41%
|
-0.02
-194.44%
|
0.02
-77.78%
|
0.08
|
| Investing Cash Flow |
|
11.25
+35.77%
|
8.28
+74.16%
|
4.76
+108.33%
|
-57.12
|
| Cash Flow From Continuing Investing Activities |
|
11.25
+35.77%
|
8.28
+74.16%
|
4.76
+108.33%
|
-57.12
|
| Net PPE Purchase And Sale |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Purchase Of PPE |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Capital Expenditure |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Net Investment Purchase And Sale |
|
11.55
+38.86%
|
8.32
+70.83%
|
4.87
+108.56%
|
-56.85
|
| Purchase Of Investment |
|
-82.92
+26.98%
|
-113.55
+17.19%
|
-137.13
-59.73%
|
-85.85
|
| Sale Of Investment |
|
94.47
-22.49%
|
121.87
-14.18%
|
142.00
+389.66%
|
29.00
|
| Financing Cash Flow |
|
85.53
+166.28%
|
32.12
-32.79%
|
47.79
+1447.67%
|
3.09
|
| Cash Flow From Continuing Financing Activities |
|
85.53
+166.28%
|
32.12
-32.79%
|
47.79
+1447.67%
|
3.09
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Net Common Stock Issuance |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
| Proceeds From Stock Option Exercised |
|
34.52
+610.10%
|
4.86
+746.86%
|
0.57
+25.33%
|
0.46
|
| Net Other Financing Charges |
|
—
|
—
|
-2.78
|
—
|
| Changes In Cash |
|
47.73
+313.12%
|
11.55
+88.67%
|
6.12
+105.75%
|
-106.50
|
| Beginning Cash Position |
|
25.31
+83.97%
|
13.76
+80.20%
|
7.64
-93.31%
|
114.14
|
| End Cash Position |
|
73.05
+188.56%
|
25.31
+83.97%
|
13.76
+80.20%
|
7.64
|
| Free Cash Flow |
|
-49.34
-70.85%
|
-28.88
+37.94%
|
-46.54
+11.77%
|
-52.74
|
| Amortization Of Securities |
|
-0.08
+82.16%
|
-0.45
-180.25%
|
-0.16
-67.01%
|
-0.10
|
| Common Stock Issuance |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
| Issuance Of Capital Stock |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-20 View
- 8-K2026-03-20 View
- 10-K2026-03-20 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 8-K2026-01-26 View
- 8-K2026-01-13 View
- 42026-01-09 View
- 8-K2026-01-06 View
- 8-K2025-12-15 View
- 42025-12-11 View
- 8-K2025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|